# US 2023/0406856 A1 · SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3, 4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0406856 A1
- Document ID: US20230406856A1
- Status: Published application
- Kind: A1
- Application number: 18/253,252
- Filed: 2021-11-16
- Published: 2023-12-21
- Earliest claimed: 2020-11-17
- Assignees: Fochon Biosciences, Ltd.
- Applicants: Fochon Biosciences, Ltd.
- Inventors: Haohan TAN; Qihong LIU; Yunling WANG; Lihua JIANG; Shu LIN; Xingdong ZHAO; Weibo WANG
- Web page: https://patentgrep.com/patent/US20230406856A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are certain BTK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

## Claims

### Claim 1

A compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is selected from C1-10 alkyl and C3-10 cycloalkyl, wherein the alkyl and cycloalkyl are each unsubstituted or substituted with at least one substituent, independently selected from RX;
each R2 is independently selected from halogen and methyl;
each RX is independently selected from C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, C3-10 cycloalkyl-C1-4 alkyl, heterocyclyl, heterocyclyl-C1-4 alkyl, aryl, aryl-C1-4 alkyl, heteroaryl, heteroaryl-C1-4 alkyl, halogen, CN, —NO2, —NRaRb, —ORa, —SRa, —S(O)rRa, —S(O)2ORa, —OS(O)2Rb, —S(O)rNRaRb, —P(O)RaRb, —P(O)(ORa)(ORb), —(CRcRd)NRaRb, —(CRcRd)tORb, —(CRcRd)tSRb, —(CRcRd)tS(O)rRb, —(CRcRd)tP(O)RaRb, —(CRcRd)tP(O)(ORa)(ORb), —(CRcRd)tCO2Rb, —(CRcRd)tC(O)NRaRb, —(CRcRd)tNRaC(O)Rb, —(CRcRd)tNRaCO2Rb, —(CRcRd)tOC(O)NRaRb, —(CRcRd)tNRaC(O)NRaRb, —(CRcRd)tNRaSO2NRaRb, —NRa(CRcRd)NRaRb, —O(CRcRd)tNRaRb, —S(CRcRd)tNRaRb, —S(O)r(CRcRd)tNRaRb, —C(O)Ra, —C(O)(CRcRd)tORb, —C(O)(CRcRd)tNRaRb, —C(O)(CRcRd)tSRb, —C(O)(CRcRd)tS(O)rRb, —CO2Rb, —CO2(CRcRd)tC(O)NRaRb, —OC(O)Ra, —C(O)NRaRb, —NRaC(O)Rb, —OC(O)NRaRb, —NRaC(O)ORb, —NRaC(O)NRaRb, —NRaS(O)rRb, —CRa(═N—ORb), —C(═NRe)Ra, —C(═NRe)NRaRb, —NRaC(═NRe)NRaRb, —CHF2, —CF3, —OCHF2 and —OCF3, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from OH, CN, amino, halogen, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, C1-10 alkoxy, C3-10 cycloalkoxy, C1-10 alkylthio, C3-10 cycloalkylthio, C1-10 alkylamino, C3-10 cycloalkylamino and di(C1-10 alkyl)amino;
each Ra and each Rb are independently selected from hydrogen, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, C3-10 cycloalkyl-C1-4 alkyl, C1-10 alkoxy, C3-10 cycloalkoxy, C1-10 alkylthio, C3-10 cycloalkylthio, C1-10 alkylamino, C3-10 cycloalkylamino, di(C1-10 alkyl)amino, heterocyclyl, heterocyclyl-C1-4 alkyl, aryl, aryl-C1-4 alkyl, heteroaryl and heteroaryl-C1-4 alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, cycloalkoxy, alkylthio, cycloalkylthio, alkylamino, cycloalkylamino, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from halogen, CN, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, OH, C1-10 alkoxy, C3-10 cycloalkoxy, C1-10 alkylthio, C3-10 cycloalkylthio, amino, C1-10 alkylamino, C3-10 cycloalkylamino and di(C1-10 alkyl)amino;
or Ra and Rb together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 12 members containing 0, 1 or 2 additional heteroatoms independently selected from oxygen, sulfur, nitrogen and phosphorus, and optionally substituted with 1 or 2 substituents, independently selected from halogen, CN, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, OH, C1-10 alkoxy, C3-10 cycloalkoxy, C1-10 alkylthio, C3-10 cycloalkylthio, amino, C1-10 alkylamino, C3-10 cycloalkylamino and di(C1-10 alkyl)amino;
each Rc and each Rd are independently selected from hydrogen, halogen, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, C3-10 cycloalkyl-C1-4 alkyl, C1-10 alkoxy, C3-10 cycloalkoxy, C1-10 alkylthio, C3-10 cycloalkylthio, C1-10 alkylamino, C3-10 cycloalkylamino, di(C1-10 alkyl)amino, heterocyclyl, heterocyclyl-C1-4 alkyl, aryl, aryl-C1-4 alkyl, heteroaryl and heteroaryl-C1-4 alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, cycloalkoxy, alkylthio, cycloalkylthio, alkylamino, cycloalkylamino, heterocyclyl, aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, independently selected from halogen, CN, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, OH, C1-10 alkoxy, C3-10 cycloalkoxy, C1-10 alkylthio, C3-10 cycloalkylthio, amino, C1-10 alkylamino, C3-10 cycloalkylamino and di(C1-10 alkyl)amino;
or Rc and Rd together with the carbon atom(s) to which they are attached form a ring of 3 to 12 members containing 0, 1 or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1 or 2 substituents, independently selected from halogen, CN, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10 cycloalkyl, OH, C1-10 alkoxy, C3-10 cycloalkoxy, C1-10 alkylthio, C3-10 cycloalkylthio, amino, C1-10 alkylamino, C3-10 cycloalkylamino and di(C1-10 alkyl)amino;
each Re is independently selected from hydrogen, CN, NO2, C1-10 alkyl, C3-10 cycloalkyl, C3-10 cycloalkyl-C1-4 alkyl, C1-10 alkoxy, C3-10 cycloalkoxy, —C(O)C1-4 alkyl, —C(O)C3-10 cycloalkyl, —C(O)OC1-4 alkyl, —C(O)OC3-10 cycloalkyl, —C(O)N(C1-4 alkyl)2, —C(O)N(C3-10 cycloalkyl)2, —S(O)2C1-4 alkyl, —S(O)2C3-10 cycloalkyl, —S(O)2N(C1-4 alkyl)2 and —S(O)2N(C3-10 cycloalkyl)2;
m is selected from 0, 1, 2, 3, 4 and 5;
each r is independently selected from 0, 1 and 2;
each t is independently selected from 0, 1, 2, 3 and 4.

### Claim 2 (depends on 1)

The compound of claim 1 or the pharmaceutically acceptable salt thereof, wherein R1 is selected from —CD3, methyl, ethyl, isopropyl and cyclopropyl, and the methyl, ethyl, isopropyl and cyclopropyl are each unsubstituted or substituted with at least one substituent independently selected from RX.

### Claim 3 (depends on 2)

The compound of claim 2 or the pharmaceutically acceptable salt thereof, wherein Rt is selected from —CD3, methyl, ethyl, isopropyl and cyclopropyl.

### Claim 4 (depends on 2)

The compound of claim 2 or the pharmaceutically acceptable salt thereof, wherein each RX is independently selected from halogen, CN, —NO2, —NRaRb, —ORa, —SRa, —S(O)rRa, —S(O)2ORa, —OS(O)2Rb, —S(O)rNRaRb, —(CRcRd)tNRaRb, —(CRcRd)tORb, —(CRcRd)tSRb, —(CRcRd)tS(O)rRb, —(CRcRd)tCO2Rb, —C(O)Ra, —C(O)(CRcRd)tSRb, —CO2Rb, —OC(O)Ra, —C(O)NRaRb, —NRaC(O)Rb, —OC(O)NRaRb, —NRaC(O)ORb, —NRaS(O)rRb, —CHF2, —CF3, —OCHF2 and —OCF3.

### Claim 5 (depends on 4)

The compound of claim 4 or the pharmaceutically acceptable salt thereof, wherein each RX is independently selected from halogen, CN, —NO2, —NH2, —OH, CHF2, —CF3, —OCHF2 and —OCF3.

### Claim 6 (depends on 1)

The compound of claim 1 or the pharmaceutically acceptable salt thereof, wherein m is selected from 0, 1, 2, 3 and 4.

### Claim 7 (depends on 6)

The compound of claim 6 or the pharmaceutically acceptable salt thereof, wherein m is selected from 0, 1 and 2.

### Claim 8 (depends on 1)

The compound of claim 1 or the pharmaceutically acceptable salt thereof, wherein each R2 is independently selected from F, Cl, Br and methyl.

### Claim 9 (depends on 8)

The compound of claim 8 or the pharmaceutically acceptable salt thereof, wherein each R2 is independently selected from F, Cl and methyl.

### Claim 10 (depends on 9)

The compound of claim 9 or the pharmaceutically acceptable salt thereof, wherein R2 is F.

### Claim 11 (depends on 1)

The compound of claim 1 or the pharmaceutically acceptable salt thereof, wherein the moiety
in Formula (I) is selected from phenyl,

### Claim 12 (depends on 11)

The compound of claim 11 or the pharmaceutically acceptable salt thereof, wherein the moiety
in Formula (I) is selected from phenyl,

### Claim 13

A compound selected from
and pharmaceutically acceptable salts thereof.

### Claim 14 (depends on 1)

A pharmaceutical composition, comprising the compound of claim 1 or the pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.

### Claim 15 (depends on 1)

A method of treating, ameliorating or preventing a condition which responds to inhibition of BTK, comprising administering to a subject in need thereof an effective amount of the compound of claim 1, or the pharmaceutically acceptable salt thereof, and optionally in combination with a second therapeutic agent.

### Claim 16 (depends on 1)

A method of treating a cell-proliferative disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 1 or the pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the cell-proliferative disorder is B-cell proliferative disorder.

### Claim 18 (depends on 17)

The method of claim 17, wherein the B-cell proliferative disorder is selected from the group consisting of; B-cell malignancies, B-cell chronic lymphocytic lymphoma, chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, multiple sclerosis, small lymphocytic lymphoma, mantle cell lymphoma, B-cell non-Hodgkin's lymphoma, activated B-cell like diffuse large B-cell lymphoma, multiple myeloma, diffuse large B-cell lymphoma, follicular lymphoma, primary effusion lymphoma, burkitt lymphoma/leukemia, lymphomatoid granulomatosis, and plasmacytoma.

### Claim 19 (depends on 14)

A method of treating, ameliorating or preventing a condition which responds to inhibition of BTK, comprising administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 14, and optionally in combination with a second therapeutic agent.
